Louise Polte
Brandenburg An Der Havel, BB, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Relating Improvement in Gastrointestinal (CFAbd-Score©) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients.
Journal: Pediatric pulmonology
Published: August 15, 2025
Improvement of abdominal symptoms in people with Cystic Fibrosis during therapy with Elexacaftor/Tezacaftor/Ivacaftor brings gastrointestinal involvement into the paediatric pulmonologist's focus.
Journal: Klinische Padiatrie
Published: May 06, 2025
The novel CFAbd-Score.kidⒸ reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor - first results.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: July 22, 2024
Scoring Abdominal Symptoms in People with Cystic Fibrosis.
Journal: Journal of clinical medicine
Published: February 02, 2024
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
Journal: Frontiers in pharmacology
Published: April 17, 2023
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
Journal: Frontiers in pharmacology
Published: March 07, 2023
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
Journal: Frontiers in pharmacology
Published: February 17, 2022
The acute effect in performing common range of motion tests in healthy young adults: a prospective study.
Journal: Scientific reports
Published: January 16, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026